
|Articles|May 15, 2004
AMO redefines position with Pfizer purchase
Advanced Medical Optics (AMO, Santa Ana, CA) redefined its position in the ophthalmic community when it reached a definitive agreement April 21 to acquire Pfizer's surgical ophthalmology business for $450 million in cash. The deal will boost AMO's revenue base by 25% and allow the company bragging rights to the Healon line of viscoelastic products, the CeeOn and Tecnis IOLs, and the Baerveldt glaucoma shunt.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Optigo: Lead anti-VEGF program advancing toward IND-enabling studies
2
AAO 2025: Advancements in laser refractive surgery
3
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
4
From then to next: Five decades of transformation in ophthalmology
5


















































.png)


